Capstone Capital Management Ltd Makes New Investment in Insulet Corporation $PODD

Capstone Capital Management Ltd purchased a new position in shares of Insulet Corporation (NASDAQ:PODD) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,446 shares of the medical instruments supplier’s stock, valued at approximately $979,000. Insulet makes up 0.9% of Capstone Capital Management Ltd’s holdings, making the stock its 29th largest holding.

Other institutional investors also recently made changes to their positions in the company. Elyxium Wealth LLC purchased a new stake in Insulet during the 4th quarter worth about $28,000. Whittier Trust Co. of Nevada Inc. lifted its holdings in Insulet by 48.9% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 43 shares in the last quarter. Measured Wealth Private Client Group LLC acquired a new stake in shares of Insulet during the 3rd quarter worth about $49,000. Osterweis Capital Management Inc. purchased a new stake in shares of Insulet during the second quarter worth about $51,000. Finally, Zions Bancorporation National Association UT raised its position in shares of Insulet by 57.3% in the third quarter. Zions Bancorporation National Association UT now owns 173 shares of the medical instruments supplier’s stock valued at $53,000 after buying an additional 63 shares during the last quarter.

Insulet Price Performance

PODD stock opened at $152.49 on Tuesday. The firm has a market cap of $10.56 billion, a P/E ratio of 35.46, a price-to-earnings-growth ratio of 1.20 and a beta of 1.20. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. Insulet Corporation has a 1 year low of $145.59 and a 1 year high of $354.88. The stock has a 50-day simple moving average of $198.16 and a 200-day simple moving average of $255.29.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. The firm had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The firm’s revenue was up 33.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities analysts predict that Insulet Corporation will post 6.44 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have weighed in on PODD. The Goldman Sachs Group set a $237.00 price target on Insulet in a report on Thursday, May 7th. JPMorgan Chase & Co. dropped their target price on Insulet from $340.00 to $275.00 and set an “overweight” rating for the company in a research note on Thursday, May 7th. Royal Bank Of Canada reduced their target price on Insulet from $325.00 to $280.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Wall Street Zen raised Insulet from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, Wells Fargo & Company lowered their price target on Insulet from $360.00 to $255.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Twenty equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $254.96.

Insider Buying and Selling at Insulet

In other Insulet news, Director Michael R. Minogue bought 2,030 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were bought at an average cost of $246.23 per share, with a total value of $499,846.90. Following the completion of the acquisition, the director owned 17,483 shares of the company’s stock, valued at approximately $4,304,839.09. This trade represents a 13.14% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.36% of the company’s stock.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.